Recent research have converged on the overlap of glucagon-like peptide-1|GIP|GCGR stimulant therapies and DA signaling. While GCGR agonists are widely employed for addressing type 2 T2DM, their emerging impacts on motivation circuits, specifically mediated by dopaminergic pathways, are attracting